MURA - Mural Oncology plc

MURA - Mural Oncology plc

https://www.muraloncology.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Mural Oncology ( MURA ) Q2 Loss Widens 49%

Motley Fool • 1 month, 1 week ago • score: 0.07

Mural Oncology ( NASDAQ:MURA ) , a biotechnology company that previously focused on developing immunotherapy drugs for cancer, announced its second quarter 2025 results on August 4, 2025. The critical news: Mural Oncology fully discontinued all research and development ( R&D ) programs, including ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$4.74

52W Low

$0.95

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.61

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

13.03%

Institutions (25–75% balanced)

57.53%

Shares Outstanding

17,324,800

Float

12,281,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-8.58

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.12%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0068

Previous

0.0051

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025